The finding that stromal cell-induced fulvestrant resistance was accompanied by changes in TMEM26 expression [10] prompted us to study TMEM26 expression in fulvestrant-treated MCF-7 cells and in fulvestrant-resistant MCF-7 and T47D breast cancer cell lines. Here, TMEM26 is linked to breast carcinoma.